AI in Clinical Trials Market

The report "AI in Clinical Trials Market by Function (Patient Recruitment, Site Optimization, Data Management, Quality, Regulatory), Phase (I, II, III), Indication (Cancer, CNS, CVS), Tool, End-User (Pharma/Biotech, CRO, Hospitals) & Region - Global Forecast to 2030", is projected to reach USD 2.74 billion by 2030 from USD 1.35 billion in 2024, at a CAGR of 12.4 % from 2024 to 2030.

Browse 358 market data Tables and 58 Figures spread through 372 Pages and in-depth TOC on "AI in Clinical Trials Market by Function (Patient Recruitment, Site Optimization, Data Management, Quality, Regulatory), Phase (I, II, III), Indication (Cancer, CNS, CVS), Tool, End-User (Pharma/Biotech, CRO, Hospitals) & Region - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/ai-in-clinical-trials-market-42687548.html

Several significant reasons drive the AI in clinical trials market. Primarily, AI accelerates data processing, allowing for significantly more efficient trial designs, patient enrolment, and real-time monitoring. AI can improve candidate selection while also decreasing trial time and cost. Pressure from upstream to downstream to make drug development more streamlined, combined with massive clinical data, has prompted the introduction of AI. Furthermore, regulatory support for AI applications in healthcare, such as trials, has promoted the use of sophisticated analytics to improve patient care outcomes and trial efficiency.

End-to-end solutions segment accounted for the largest share of the AI in clinical trials market in 2023, by offering.

End-to-end solutions segment accounted for the largest market share in the AI in clinical trials market in 2023, by offering, as end-to-end solutions offer complete support throughout the trial process, including recruitment and patient monitoring, and also data analysis and regulatory submission. These are the pharmaceutical and biotech companies that usually does the main part of the process, for instance, streamlining operations, reducing costs, and improving efficiencies by integrating several trial stages under a single supplier, thus, making a great contribution to the sector in a highly competitive landscape.

The phase III segment to account for largest share of AI in clinical trials market for the year 2023, by phase

In AI in clinical trials market, Phase III segment will have largest share due to large-scale drug efficacy and safety testing among varied patient populations for regulatory approval and commercialization. Tools used in Phase III with the support of AI mobilize huge data collection, patient monitoring, and predictive analytics. The high price, complexity, and regulatory importance of Phase III trials encourage investment in AI for streamlining and saving time with guaranteed successful outcomes of the trial.

North America accounted for the largest share of the AI in clinical trials market in 2023.

North America held the most significant market share in the AI in clinical trials market in 2023. This region has a developed infrastructure concerning healthcare, the region has significant investments in R&D compared to their Asian counterparts, and it is home to leading pharmaceutical and biotechnology companies. Moreover, in North America, the regulatory environment and agencies like FDA support the integration of AI in clinical trials for better clinical trial processes. Well, highly adopted digital technologies and robust availability of data have pushed forward the fast implementation of AI solutions across, which has allowed for even more efficient trial designs, patient recruitments, and real-time analysis of data.

Prominent players in the AI in clinical trials market include are IQVIA Inc. (US), Saama. (US), Dassault Systèmes (Medidata) (France), Phesi (US), PathAI, Inc. (US), Unlearn.ai, Inc. (US), Deep6.ai (US), Microsoft (US), IBM (US), NVIDIA Corporation (US), Insilico Medicine (US), ConcertAI. (US), AiCure. (US), Median Technologies. (France), Lantern Pharma Inc. (US), Citeline, a Norstella Company (US), Tempus AI, Inc. (US), TriNetX, LLC (US), ReviveMed Inc. (US), Euretos. (US), VeriSIM Life. (US), Triomics (US), Ardigen (Poland), QuantHealth Ltd. US), and DEEP GENOMICS. (Canada).

Don’t miss out on business opportunities in AI in Clinical Trials Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]